Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22694
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanderson, Emma-
dc.contributor.authorWimaleswaran, Hari-
dc.contributor.authorSenko, Clare-
dc.contributor.authorWhite, Shane-
dc.contributor.authorMcDonald, Christine F-
dc.date2020-02-25-
dc.date.accessioned2020-03-02T03:28:02Z-
dc.date.available2020-03-02T03:28:02Z-
dc.date.issued2020-04-
dc.identifier.citationRespirology Case Reports 2020; 8(3): e00542en_US
dc.identifier.issn2051-3380-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22694-
dc.description.abstractImmune checkpoint inhibitors (ICIs) have become pivotal in the treatment of lung cancer. An increasing number of immune-related adverse events (irAEs) have been recognized with their use. To our knowledge, this is the first published case of sarcoid-like pulmonary lymphadenopathy associated with durvalumab, a monoclonal antibody against programmed death ligand-1 (PD-L1). A 76-year-old woman received adjuvant durvalumab for Stage IIA pT2aN1M0 (American Joint Committee on Cancer, Seventh edition) poorly differentiated lung adenocarcinoma. After three cycles, a sarcoid-like granulomatous reaction was identified in mediastinal and hilar lymph nodes. Although the lymphadenopathy remained stable in size with the ongoing treatment, progressive intracranial metastases were identified after a further three cycles of durvalumab. Sarcoid-like inflammation with the formation of non-caseating granulomas in the absence of systemic sarcoidosis is an irAE which may mimic disease progression. Although a subset of patients who experience this reaction may have a favourable response to checkpoint inhibition, progression of disease may occur contemporaneously.en_US
dc.language.isoeng-
dc.subjectDurvalumaben_US
dc.subjectimmune checkpoint inhibitionen_US
dc.subjectsarcoidosisen_US
dc.titleDurvalumab induced sarcoid-like pulmonary lymphadenopathy.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleRespirology Case Reportsen_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.affiliationFaculty of Medicine, Dentistry and Health Sciences University of Melbourne Melbourne VIC Australiaen_US
dc.identifier.doi10.1002/rcr2.542en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-6481-3391en_US
dc.identifier.orcid0000-0002-4605-3891en_US
dc.identifier.pubmedid32110415-
dc.type.austinCase Reports-
local.name.researcherMcDonald, Christine F
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Jun 17, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.